Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

FDA approves ABBV’s Rinvoq (upadacitinib) for RA:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 727
Posts 109,871
Boards Moderated 15
Alias Born 09/05/02
160x600 placeholder
AbbVie conclut une entente avec l'Alliance pancanadienne pharmaceutique (APP) relativement à SKYRIZI[MC] (risankizumab) pour... PR Newswire (Canada) - 12/6/2019 6:08:00 AM
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatm... PR Newswire (Canada) - 12/6/2019 6:08:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 12/5/2019 9:39:00 AM
Form 8.3 - Allergan Plc Dow Jones News - 12/4/2019 9:54:00 AM
Form 8.3 - Allergan Plc Dow Jones News - 12/3/2019 10:43:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 12/2/2019 9:59:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/27/2019 10:04:00 AM
Form 8.3 - Allergan Plc Dow Jones News - 11/26/2019 10:07:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 11/25/2019 9:13:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/22/2019 10:03:00 AM
Harpoon Therapeutics Shares Rise on Expanded Deal With AbbVie Dow Jones News - 11/21/2019 12:35:00 PM
Form 8.3 - [Allergan plc] Dow Jones News - 11/21/2019 9:45:00 AM
Harpoon, AbbVie Ink New, Expanded Agreements Dow Jones News - 11/21/2019 8:58:00 AM
AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annua... PR Newswire (US) - 11/21/2019 8:30:00 AM
Dragonfly Therapeutics annonce une collaboration avec AbbVie visant les maladies auto-immunes et l'oncologie PR Newswire (Canada) - 11/21/2019 7:35:00 AM
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting Tri... GlobeNewswire Inc. - 11/21/2019 4:00:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 11/20/2019 9:47:00 AM
Dragonfly Therapeutics to Collaborate With AbbVie Dow Jones News - 11/20/2019 9:44:00 AM
Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology PR Newswire (US) - 11/20/2019 8:00:00 AM
Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology PR Newswire (Canada) - 11/20/2019 8:00:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/19/2019 9:55:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 11/18/2019 9:48:00 AM
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes PR Newswire (US) - 11/18/2019 8:00:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/15/2019 9:42:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/14/2019 9:49:00 AM
DewDiligence Member Level  Friday, 08/16/19 03:04:21 PM
Re: None
Post # of 513 
FDA approves ABBV’s Rinvoq (upadacitinib) for RA:

https://finance.yahoo.com/news/abbvie-receives-fda-approval-rinvoq-164300881.html

https://finance.yahoo.com/news/1-fda-approves-abbvies-rheumatoid-164927079.html

Rinvoq is an oral JAK inhibitor; it is one of the drugs ABBV is counting on to make up the slack as Humira sales decline from the uptake of biosimilars.

The US list price of Rinvoq is ~$59K per annum, which is slightly less than Humira.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist